GadoSpin F is an amphiphilic gadolinium-based contrast agent with high protein-binding affinity specifically formulated for preclinical magnetic resonance imaging (MRI).
It is a contrast agent of high relaxivity increasing the signal intensity in T1-weighted MRI due to a shortening of the spin-lattice relaxation time (T1).
Upon intravenous injection, GadoSpin F rapidly binds to plasma proteins. This protein binding extends the residence time of the drug in the vascular space and, consequently, prolongs the imaging time window. Accumulation in atherosclerotic plaques can be observed allowing for direct visualization of plaque burden.
GadoSpin F is excreted in feces and urine.
Applications
GadoSpin F is indicated for use in MRI of small animals, for example mice, to facilitate the visualization of the vasculature.
Examples include contrast-enhanced magnetic resonance angiography (MRA) and detection of atherosclerotic plaques.
Zheng, J. et al. (2008) Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Invest. Radiol. 43: 49-55
Raatschen, H. J. et al. (2006) MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent. Contrast Media Mol. Imaging 1: 113-120
Barkhausen, J. et al. (2003) Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging. Circulation 108: 605-609